The first and only IVIg stabilized with proline

Maintaining the stability of IgG is crucial for preserving an antibody's functionality and efficacy in IVIg preparation. That's why Privigen is formulated with 250 mmol/L of the amino acid stabilizer proline at pH 4.8.^1,2 Proline is a naturally occurring amino acid, a critical component of human physiology, and a normal component of the human diet. It was specifically chosen as the stabilizer after extensive testing and analysis.^2,3

Features of proline stabilization include²:

Reduced IgG aggregation
Reduced dimer formation
Minimized fragmentation

Prevention of solution discoloration
Room-temperature storage*

*Up to 36-month room-temperature storage, as indicated by the expiration date printed on the outer carton and vial label.

How proline works

Proline interacts with hydrophobic groups in the IgG molecule, thereby reducing protein-protein association and dimerization; in other words, it stabilizes IgG molecules as monomers.² The images below show dimer formation in IgG solutions with proline and without proline.

Dimer fomation occurs without proline

In solution, IgG molecules (shown in blue) reversibly bind to each other (circled).²

Proline inhibits dimer formation and stabilizes IgG molecules

Proline reduces dimer formation

Proline may shield IgG molecules from binding together.²

Proline is rapidly cleared from circulation and does not accumulate after treatment.^†3 Privigen is contraindicated in patients with hyperprolinemia.

†Clinical significance is unknown.

Designed for tolerability in a wide range of patients⁴

Privigen may be an option for patients with diabetes, latex allergy, and sensitivity to preservatives

Designed for stability, Privigen is also safe and effective

See how Privigen did in clinical studies

View the studies

References: 1. Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen^®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225. 2. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157. 3. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745. 4. Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587